<?xml version="1.0" ?>
<GlossaryTerm id="CDR0000777246">
  <TermName>Empliciti</TermName>
  <TermPronunciation>(em-PLIH-sih-tee)</TermPronunciation>
  <TermDefinition>
    <DefinitionText>A drug used with dexamethasone and either lenalidomide or pomalidomide to treat adults with multiple myeloma. It is used in patients whose cancer was already treated with other anticancer therapies. Empliciti binds to a protein called CS1, which is found on myeloma cells and some types of immune cells. Empliciti may block CS1 and help the immune system kill cancer cells. It is a type of monoclonal antibody. Also called elotuzumab and HuLuc63.</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </TermDefinition>
  <MediaLink ref="CDR0000778427" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;Empliciti&quot;" language="en" id="_3"/>
  <MediaLink ref="CDR0000778426" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;Empliciti&quot;" language="es" id="_4"/>
  <SpanishTermName>Empliciti</SpanishTermName>
  <SpanishTermDefinition>
    <DefinitionText>Medicamento que se usa con
dexametasona y lenalidomida o pomalidomida para el tratamiento de adultos con mieloma
múltiple. Se administra a pacientes que ya recibieron otros tratamientos para su cáncer.
Empliciti se une a una proteína llamada CS1, que se encuentra en las células de mieloma y en
algunos tipos de células inmunitarias.
Es posible que Empliciti bloquee la CS1 y ayude al
sistema inmunitario a destruir células cancerosas. Es un
tipo de anticuerpo
monoclonal. También se llama elotuzumab y HuLuc63.</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </SpanishTermDefinition>
  <DateFirstPublished>2015-12-02</DateFirstPublished>
  <DateLastModified>2020-08-20</DateLastModified>
  <RelatedInformation>
    <RelatedDrugSummaryRef UseWith="en" href="CDR0000777260" url="/about-cancer/treatment/drugs/elotuzumab">Elotuzumab</RelatedDrugSummaryRef>
  </RelatedInformation>
</GlossaryTerm>
